by Written on behalf of Wise Health Law June 28, 2018 3 min read

We’ve previously blogged about medical assistance in dying (MAID), including a challenge filed to the CPSO’s policy on effective referral for assisted dying and a request for the Justice Minister to grant an immediate moratorium on all medically assisted deaths until governing legislation is changed to ensure that all necessary services are in place to assist patients. It is clear that the MAID legislation, which the federal government passed two years ago, has resulted in multi-faceted discussion and debate around the various implications of the legislation, as well as various components of the legislation itself. Recently, CBC News reported that there were 1,523 medically assisted deaths in Canada in the last six months- an increase of almost 30% since the previous six months.

Some Statistics

The above figure accounted for 1.07% of all deaths in Canada in that period of time, and is consistent with reports from other jurisdictions which offer assisted death, where this number ranges from 0.3 to 4%. Since the federal MAID legislation came into force two years ago, 3,714 Canadians have received medical aid in dying. The majority of Canadians choosing assisted death are between 56 and 90 years old, with the average age being 73 years old. The most common underlying condition resulting in people seeking MAID was cancer, which was cited in 65% of cases. Unlike in other jurisdictions such as the Netherlands where more than 80% of its assisted deaths occurred at home, in Canada the setting for MAID is usually a hospital (40.5%), a patients home (43.3%), or a long-term care facility. There were more cases of MAID in larger urban centres (55.9%) compared to areas with smaller populations (41.6%). The CEO of Dying with Dignity Canada noted that she was not surprised to see the numbers increasing, but noted that the eligibility criteria too restrictive and that many Canadians still face too many barriers to an assisted death. She noted that many Canadians die before the assessment process is complete:
"If their health is already precarious, the longer it takes to get the help they need, the greater (the risk) is that they will lose capacity or die before they're able to complete their request."

Constitutional Challenge

The British Columbia Civil Liberties Association (BCCLA) filed a constitutional challenge to the MAID legislation within 10 days of it being passed, arguing that the legislation violates the Charterrights of Canadians. The legislation requires that the death of the person seeking MAID must be “reasonably foreseeable”. The BCCLA’s lawsuit was filed on behalf of a B.C. woman with spinal muscular atrophy. The woman fears that her condition will cause her years of unbearable physical and mental suffering, but that she will be unable to receive MAID because her natural death is not “reasonably foreseeable”. The federal government launched independent reviews following the passing of the legislation in order to decide whether it should be expanded to cover Canadians suffering from mental illness, mature minors, and those with conditions that may erode their competence and who wish to make advance plans for their death. We will continue to follow the ongoing debate over MAID in Canada and will provide information as this discussion unfolds. At Wise Health Law,we are passionate about helping healthcare organizations, regulated health professionals, and regulated health professional associations understand and protect their legal rights. We follow developments in the law and are consistently at the forefront of change and innovation. For the convenience of our clients, we have offices in both Toronto and Oakville, Ontario, and are easily accessible. Contact us online, or at 416-915-4234 for a consultation.


Also in Blog

Cases to Watch: Marchi v. Nelson

by Mina Karabit September 22, 2020 3 min read

In August 2020, the Supreme Court heard and granted leave to appeal in Marchi v. Nelson, a case from the British Columbia Court of Appeal. The decision is one to watch as it will likely result in a renewed discussion of the distinction of policy versus operational decisions and their impacts on liability in tort law. The discussion will likely impact many of the anticipated post-COVID-19 lawsuits against public and government institutions.
Judicial Review: New Time Limits and a Helpful Primer

by Mina Karabit September 17, 2020 4 min read

In December 2019, Ontario’s Attorney General introduced Bill 161, the Smarter and Stronger Justice Act (the “Act”), which became law on July 8, 2020. The Act hopes to simplify a complex and outdated justice system by bringing changes to how legal aid services are delivered, how class actions are handled, and how court processes are administered.

Of note, the Act has amended the Judicial Review Procedures Act (JRPA) to establish new rules as to when an application for judicial review may be brought.

Any decisions made on or after July 8, 2020 are now subject to a 30-day limit for bringing an application for judicial review unless another Act provides otherwise. Courts, however, retain powers to extend the time for making an application for judicial review if satisfied that there are apparent grounds for relief and that no prejudice or hardship will be incurred by the delay. Before these amendments, the JRPA did not set out any time limits for bringing an application, but courts had powers to extend the time to bring an application if another Act prescribed the limit.

Recent Exemptions for Psychedelic Therapy in Canada

by Mina Karabit August 14, 2020 3 min read

In early August 2020, the Federal Minister of Health granted an exemption under the Controlled Drugs and Substances Act (CDSA) to four terminally ill Canadians to use psilocybin in their end of life care.

Psilocybin is one of the active ingredients/chemicals in “magic mushrooms,” the other is psilocin. Both psilocybin and psilocin are controlled substances under Schedule III of the CDSA. The sale, possession, production, etc. are prohibited unless authorized for clinical trial or research purposes under Part J of the Food and Drug Regulations. Both have been illegal in Canada since 1974. According to Health Canada, there are no approved therapeutic products containing psilocybin in Canada. However, the purified active ingredient, i.e. psilocybin, is being studied in supervised clinical settings for its potential to treat various conditions such as anxiety and depression.